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One of the top research priorities of the international AIDS society by the action 
“Towards an HIV Cure” is the purge or the decrease of the pool of all latently infected 
cells. This strategy is based on reactivation of latently reservoirs (the shock) followed 
by an intensifying combination antiretroviral therapy (cART) to kill them (the kill). The 
central nervous system (CNS) has potential latently infected cells, i.e., perivascular 
macrophages, microglial cells, and astrocytes that will need to be eliminated. However, 
the CNS has several characteristics that may preclude the achievement of a cure. In this 
review, we discuss several limitations to the eradication of brain reservoirs and how we 
could circumvent these limitations by making it efforts in four directions: (i) designing 
efficient latency-reversal agents for CNS-cell types, (ii) improving cART by targeting HIV 
transcription, (iii) improving delivery of HIV drugs in the CNS and in the CNS-cell types, 
and (iv) developing therapeutic immunization. As a prerequisite to these efforts, we also 
believe that a better comprehension of molecular mechanisms involved in establishment 
and persistence of HIV latency in brain reservoirs are essential to design new molecules 
for strategies aiming to achieve a cure for instance the “shock and kill” strategy.
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iNTRODUCTiON
Combination antiretroviral therapy (cART), introduced in 1996, has radically improved the man-
agement of HIV-1 infection and decreased both morbidity and mortality. However, despite initial 
hopes to cure HIV, treatments were unable to fully eliminate the virus (1–3). Indeed, with very 
sensitive methods (4–6), a remaining viremia is always noticed in patients on cART. Moreover, 
HIV RNA returns to a measurable plasma level when cART is disrupted (7, 8). The origin of this 
persistent viremia is still a matter of debate (9–11). Latent persistence of HIV in long-lived cells, 
such as the central memory CD4+ T-cells, hematopoietic stem cells, dendritic cells, and cells from 
the monocyte–macrophages lineage in the form of proviruses have been described (1, 2, 12–19). 
Moreover, these cells are located in a variety of anatomical sites, including tissues, such as blood, 
brain, gut-associated lymphoid tissue, bone marrow, and genital tract (20), making it difficult to 
purge the virus from all the reservoirs.
These latently infected cells are from time to time reactivated and produce HIV particles at low 
levels, thus explaining the persistence of viremia. An alternative theory, the cryptic ongoing replica-
tion states that despite cART, HIV is continuously produced at low levels. The inefficiency of the 
treatment in cells supporting ongoing replication could be due to poor drug penetration in sanctuar-
ies, such as the brain (21) or by cell-to-cell transfer of the virus (22). In theory, there are critical 
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therapeutic implications for cART as it is expected that during 
ongoing replication, drug resistance might arise (23–26). The 
potential mechanisms of HIV persistence have been discussed 
recently in a review by Hong and Mellors (27).
One of the main debates in the field of HIV reservoir is whether 
or not the central nervous system (CNS) constitutes a real viral 
reservoir. Indeed, with its unique features, such as the existence 
of a blood–brain barrier (BBB) with poor drug penetration, the 
CNS might be considered as a sanctuary (20) made of specific 
cell types (28) with reduced immune surveillance. Moreover, 
the anatomy of the CNS is such that there is poor viral genetic 
information exchange with the other sites and, thus, might be 
referred as a compartment (20, 29, 30).
First, we will give our opinion on the existence of viral 
reservoirs in the CNS referring to excellent recent reviews in 
this topic. Next, we will discuss the importance to purge these 
potential viral reservoirs. Indeed, in theory, it is possible to 
acquire virus resistance to cART if there is an ongoing replica-
tion in the brain. Another major concern is the existence of HIV-
associated neurocognitive disorders (HAND). In up to 50% of 
the HIV-infected patients on efficient cART and undetectable 
virus load (≤50 copies/ml), HAND has been recorded. Several 
mechanisms are evoked to explain the increase of less severe 
forms of HAND in which production of some viral proteins 
occurs during reactivation or cryptic ongoing HIV replication. 
We will then review the state of art of what is known regarding 
the molecular mechanisms underlying the establishment and 
persistence of HIV in the potential reservoirs in the brain and, 
finally, discuss the profound therapeutic implications of purging 
reservoirs.
CAN THe CNS Be QUALiFieD  
AS A Hiv ReSeRvOiR?
A viral reservoir is an infected cell population that allows persis-
tence of replication-competent virus in patients under cART (20). 
According to this definition, the only true reservoirs are the rest-
ing CD4+ T-cells. Indeed, these cells fulfill all the criteria to be 
considered as a real reservoir, i.e., presence of integrated virus in 
long-lived cells, persistence of high levels of virus in a quiescent/
latent state in the reservoir and possible reactivation of the virus 
with the formation of replication-competent particles (31).
There are several evidences that brain cells harbor genome-
integrated HIV (28). We know that the virus invades the brain 
very soon following infection. Virus infection was shown 
in astrocytes (32), in perivascular macrophages (32), and in 
microglial cells (33). All three cell types are long-lived cells with 
perivascular macrophages (34) and astrocytes (35) with a half-
life ranging from months and microglial cells with a half-life 
of years (36). All these cells are infected at high frequency in 
the brain. Astrocytes, the most abundant cell type in the brain, 
are infected in up to 19% of the cell population (37). Similar 
ratio of infected cells has been found among the perivascular 
macrophages and the microglial cells (33, 38). In addition, 
several mechanisms, including epigenetic regulation, have been 
evoked to induce latency in these cells notably in astrocytes and 
microglial cells (39–42).
Due to ethical and technical problems, it is not possible to 
evaluate the human brain-infected cells for their capacity to 
produce replication-competent viruses. However, there are 
several indirect evidences showing that CNS is a reservoir 
for HIV. Indeed, HIV DNA has been detected in brain tissues 
isolated from autopsies of HIV patients whose infection has 
been controlled by cART (33, 39). Moreover, there is a strong 
correlation of the amount of HIV DNA found in astrocytes and 
HIV-associated dementia (HAD) (37). Various animal models 
have been used to show persistence of HIV infection in the CNS 
as brain biopsy is not possible. Indeed, several animal models, 
such as macaque, rats, and humanized BLT mouse, have been 
used to mimic the condition of HIV-infected patients on cART, 
which confirmed the presence of viral RNA or viral proteins 
in the brain (43–45). Specifically, in the macaque model, a 
mechanism of the establishment of transcriptional HIV latency 
in the CNS has been suggested (46). They notably showed that 
interferon beta repressed SIV LTR activity by inducing C/
EBPγ expression, a dominant negative isoform of C/EBPβ (47). 
There are also several evidences supporting continuous CNS 
perturbation despite an efficient cART (48) with an increase of 
the prevalence of milder form of HAND. Moreover, in patients 
under suppressive cART activation of the immune system is still 
observed in the CNS with some biomarkers, such as neopterin 
or NFL being detected in the cerebrospinal fluid (CSF) (49). 
One explanation is the existence of an inflammatory process 
that might be driven by low-level HIV replication in infected 
cells (50, 51). Interestingly, neuroimaging data are also in favor 
of persistent CNS inflammation in patients on cART (52, 53). 
Finally, development of highly sensitive methods, such as single-
copy assay (SCA), has allowed the detection of HIV RNA in the 
CSF from infected patients on cART or from elite controllers 
whose HIV RNA level was initially undetectable in the plasma 
and CSF (54–56). The recent discovery of a CSF viral escape in 
patients on cART with undetectable plasma HIV RNA but with 
neurological impairment argue also for the existence of a per-
sistent HIV reservoir in the brain (55–59). In conclusion, there 
are now several evidences supporting that CNS is a reservoir for 
HIV even if it is still controversial. Readers will be referred to the 
following reviews that nourish the debate of whether or not CNS 
serves as a HIV reservoir (60–63).
wHY iS iT iMPORTANT TO PURGe 
THe CNS ReSeRvOiR OF Hiv?
The CNS is involved in the control of most functions of the 
body and mind. The brain operates in a very well controlled 
microenvironment separated from the other parts of the body 
by two barriers: the choroid plexus and the BBB. The two bar-
riers, but predominantly the BBB, constitute physical barriers 
and any perturbation of their integrity will be associated with 
neurological diseases. There are several other features that 
make the CNS unique. The CNS has specific immunological 
features; principally an innate immune response through the 
perivascular macrophages and the microglial cells. However, the 
adaptive immune response has also been observed and, thus, 
contributes to the immune surveillance in the CNS (64, 65). 
3Marban et al. HIV and CNS Reservoirs
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 397
Indeed, leukocytes trafficking to the CSF either by traversing the 
BBB to the perivascular space or the choroid plexus has been 
detected (66). More interestingly, in patients having CSF/plasma 
HIV discordance (patients having higher levels of HIV RNA in 
CSF than in blood) even at very low levels it was demonstrated 
that both innate (macrophages and microglial cells) and adaptive 
(T CD4+ and CD8+ lymphocytes) are involved in CNS injury 
(67–70). It has been shown that the percentage of a specific set 
of T CD8+ lymphocytes that expresses interferon γ is higher in 
the CSF than in blood. Moreover, this higher percentage of T 
CD8+ cells in CSF versus blood contributes to the occurrence 
of HAND (67) [reviewed in Ref. (71)]. Within 2 weeks following 
acute infection by HIV, the virus enters the CNS. There are at 
least two mechanisms to explain how HIV crosses the BBB, 
including trafficking of cell free virus and infected cells (72). The 
well-documented infection of the CNS is accomplished through 
infected cells and, thus, has been named the “Trojan Horse” 
mechanism (73). A recent study using natalizumab, an anti-α4 
blocking antibody preventing both lymphocytes and monocytes 
trafficking across the BBB, is in accordance with this mechanism. 
Indeed, a drastic decrease of SIV DNA in the brain was observed 
when natalizumab was given to rhesus macaque during acute 
SIV infection (74). According to this theory, infected monocytes 
cross the BBB and infect the perivascular macrophages, the 
microglial cells, and the astrocytes that result in HIV-associated 
neurological disorders (75). Since the introduction of cART, an 
important decrease in the incidence of the severe form of HAND 
has been noticed (76). However, there is an increase of milder 
form of the infection (up to 50%), which might be largely under 
diagnosed. Thus, better screening tools to detect HAND are 
required in the future (77). The reasons for the increase of the 
prevalence of milder forms of HAND are not fully understood. 
One explanation might be related to the existence of quiescent/
latent viral reservoirs in the CNS that emphasizes the importance 
of eradicating the reservoirs. Another major concern related to 
the existence of such quiescent/latent reservoirs in the CNS is 
that it might be a source of new particles that could replenish 
the periphery blood. These notions will be discussed in the 
later chapters.
Hiv-1 and Hiv-Associated Neurological 
Disorders
HIV-associated neurocognitive disorders have been divided into 
three subgroups according to the Frascati criteria, i.e., asymp-
tomatic neurocognitive impairment (ANI), mild neurocognitive 
disorder (MND), and HAD (78). These disorders are associated 
with the entry of HIV into the CNS that occurs almost imme-
diately after systemic infection (79). The more severe form of 
HAND, i.e., HAD has drastically decreased with the introduction 
of cART. However, the less severe forms (MND and ANI) have 
continued with a prevalence ranging from 20% to up to 50%, 
while keeping in mind that these milder forms are often under 
diagnosed (80, 81). However, the details of persistence of these 
less severe forms of HAND in patients on cART are not fully 
understood. There are at least two hallmarks of HIV infection in 
the brain, i.e., chronic immune activation and compromised BBB 
integrity in which the central role for HIV neuropathogenesis 
is played by the monocytes/macrophages (82–85). Importantly, 
immune activation still occurs in patients on cART (50, 51). 
The exact mechanisms of such pathogenesis are not entirely 
known and rely on two models: a direct and an indirect model 
(86, 87). In the direct model, infected cells will cause neuronal 
death through the action of newly synthesized viral proteins, 
such as Tat, gp120, Vpr, and Nef. The two major viral proteins 
that lead to neuronal injury are Tat and gp120. Their effects 
are mediated through their interaction with neuronal cell recep-
tors, such as the NMDA receptor and the chemokine receptors 
(CCR5 and CXCR4). More details on the mechanisms involved 
in the neuropathogenesis caused by viral proteins are found 
in the review (88). In the indirect model, sustained chronic 
inflammation is induced by secreting perivascular macrophages, 
microglial cells, and to a lesser extent by astrocytes releasing 
neurotoxic host factors. Among these secreted products, there 
are proinflamatory cytokines (TNFα, IL-1β, IL-6, IL-8, and 
INFα), chemokines (CCL2 and CCL5), and small molecules, 
such as quinolinic acid and the platelet-activating factor. 
Moreover, these viral proteins and cellular factors increase the 
oxidative stress and alter the integrity of the BBB which in 
turn results in the stimulation of even more infected cells in 
the brain. Further investigations are needed to decipher the 
exact mechanisms involved in CNS injury. Interestingly, Tat 
might be involved in both direct and indirect processes that lead 
ultimately to neuronal death. Potential roles and functions of Tat 
in both direct and indirect neurotoxicities have been described 
elsewhere (89, 90). The importance of Tat is still a matter of 
debate since there are controversies regarding the amount of Tat 
present in the CNS cells environment and the amount of Tat 
used in in  vitro experiments. In favor of its importance is the 
use of Tat transgenic animal model where CNS injury has been 
observed (91, 92). Therefore, it will be essential to detect Tat in 
the brain from patients on cART. It is possible that this protein 
might arise from quiescent/latent reservoirs and, therefore, be 
responsible for the milder form of HAND. Improvement of 
cART by targeting the production phase of HIV-1, including 
transcription appears, therefore, crucial (93). Indeed, current 
cART is not targeting this step and since the CNS infection 
occurs almost immediately during acute infection, establishment 
of infected reservoirs will not be prevented. Moreover, strategies 
aiming to purge the reservoirs are based on HIV reactivation 
with the risk that viral proteins, such as Tat will be produced 
in the brain. HIV-1-mediated neuropathogenesis might also 
involve a dynamic interaction between astrocytes and peripheral 
blood mononuclear cells (PBMCs) (94). Indeed, a recent report 
showed that astrocytes susceptibility to produce HIV infection 
is enhanced by PBMCs producing interferon γ which in turn 
inhibit HIV-1 production in PBMCs through the secretion of 
small glycoprotein, i.e., the Wtns. These later proteins have been 
shown to be involved in many CNS processes (95), such as 
synaptic plasticity and neurotransmitter release, which might 
explain partly HIV-1-mediated neuropathogenesis.
CNS Reservoirs as a Source of virus
The CNS has two special features making it difficult the 
achievement of a cure. First of all, the CNS is considered as 
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a sanctuary for HIV by pharmacologic means as it is a site 
with limited access to antiretroviral drugs (ARV) (96–99). As 
an outcome, there is a risk to allow the occurrence of virus 
resistant to the current drugs used in cART. Second, the CNS is 
also considered as a compartment in which the virus is isolated 
from other parts of the body (29, 100). Because of poor genetic 
information exchange with the other sites, neurotropic variants 
of HIV might be selected, which most likely will not respond 
to treatment in a similar way than the virus encountered in 
the CD4+ T-cells, the main target in the body. There are now 
numerous evidences supporting the fact that the CNS-resident 
virus has evolved to become macrophage tropic (101). Indeed, 
sequence analysis of the env gene and of the HIV-1 promoter 
(LTR) argue for the compartmentalization of HIV variants in 
the CNS (102–105). Variations in the promoter are important 
since mechanisms involved in the establishment and persis-
tence of latency in the CNS might differ from the one described 
in CD4+ T-cells. As mentioned above, this will impact the effi-
ciency of latency-reversing agents (LRA) in strategies aiming to 
purge the latent/quiescent reservoirs (106, 107). Another major 
concern regarding the necessity to purge the CNS reservoirs 
is related to the discovery of CNS viral escape in patients on 
cART (108). Initial studies have shown occasional cases of virus 
escapes in the CSF (109, 110). Development of highly sensitive 
assays has even allowed the detection of CSF HIV RNA, which 
were not detectable with previous assays (111). Indeed in a 
report, evaluation of CSF viral escape has been done in a cohort 
of neurologically asymptomatic patients successfully treated 
with cART. It was shown that around 10% of these patients 
had detectable CSF HIV RNA, suggesting that viral escape may 
be underestimated (112). The recent discovery of a CNS viral 
escape in a cohort of 14 patients on cART with undetectable 
plasma HIV RNA but who developed HIV-encephalitis argues 
for the possibility that CNS is a real reservoir (57). Actually, 
this study and others raise the question that CNS-specific viral 
replication can occur in patients on cART from reactivated 
reservoirs which in theory may have escaped therapy and 
ultimately lead to drugs resistance (58, 59, 113). Very interest-
ingly a similar drug-privileged site, i.e., the lymphoid tissue 
has been shown to have low access to drugs (114). The authors 
notably showed that the virus is continuously produced and 
might be a source of HIV from which replenishment of blood 
occurs. However, and contrary to the brain, they do not show 
that resistance to antiretroviral drugs arises. The authors 
of this study suggest that this absence of resistance to ARV 
might be explained by the too low level of drug concentration 
in lymphoid tissue that is not sufficient to confer competitive 
advantages to the development of drug-resistant viruses. This 
study point out to the importance of developing new ways to 
deliver drugs in all sanctuaries, including brain and lymphoid 
tissues (115).
Overall, we suggest that it is crucial to eradicate brain res-
ervoirs since ARV-resistant viruses are capable to replenish the 
systemic circulation from these reservoirs. It will also imply that 
CSF analysis in patients on cART should be performed more 
often since it will greatly help assessing the compartmentaliza-
tion of HIV in the brain and monitoring the efficiency of new 
treatments (116). Notably, CSF might be used to evaluate HIV 
drug resistance.
MOLeCULAR MeCHANiSMS OF Hiv-1 
LATeNCY
Establishment and persistence of HIV latency occur in brain cells, 
i.e., perivascular macrophages, microglial cells, and astrocytes. 
Infection of these cells differs from the infection of blood cells 
infected, mainly the CD4+ T-cells. Indeed, HIV infection in 
macrophages is not lytic and these cells are far more resistant to 
cytopathic effects. Moreover, infected monocyte–macrophage 
cells are also more resistant to apoptosis, a major obstacle for the 
eradication of the virus. These cells may harbor latent viruses 
for months (perivascular macrophages) or for years (microglial 
cells). Astrocytes are also thought to be infected by HIV-1 despite 
the lack of the co-receptors CCR5 and CXCR4 probably through 
the involvement of vesicles (38). However, the infection appears 
to be non-productive with only early transcripts, such as tat and 
nef, that are detectable at very low level (117).
Understanding the intimate mechanisms underlying HIV-1 
latency in these CNS-specific cells is necessary to develop new 
and original therapies for viral eradication. The molecular 
mechanisms underlying these therapies are determined by the 
cellular specificity of HIV gene transcription and the variability 
of the LTR found in viruses having evolved in the brain (61, 
118). For example, it has been shown in microglial cells that 
Sp3 and a truncated form of C/EBPβ (NF-IL6) inhibit the basal 
transcriptional activity of HIV-1 (47). Such a reduced basal and 
Tat-activated transcriptional activity has also been shown in 
astrocytes. Transcriptional silencing has been associated with 
low levels of TAR RNA binding proteins (TRBP) and with muta-
tions of the SP motifs found within the LTR of brain-derived 
HIV-1. Mutations prevent the transcription factor Sp1 to bind 
the promoter and, thus, inhibit transcriptional activation (119, 
120). However, the main mechanism involved in establishment 
and persistence of latency involves epigenetic regulation (41, 
121, 122). In our laboratory, we showed that the cellular factor 
COUP-TF interacting protein (CTIP2) is a key factor in the 
establishment and persistence of HIV latency in microglial cells 
(123). We notably showed that this protein serves as a platform 
to anchor several protein complexes having different functions. 
Indeed, at least two different complexes containing CTIP2 are 
involved in the establishment and the persistence of HIV-1 
latency (Figure 1). Moreover, CTIP2 is also involved in the con-
trol of cellular genes of importance for the virus. Among these 
factors, the cellular cyclin-dependent kinase inhibitor CDKN1A/
p21waf has been described to favor HIV-1 gene transcription in 
the monocyte–macrophage lineage. This effect indirectly favors 
HIV-1 latency since activation of the p21 gene stimulates viral 
expression in macrophages (124). Moreover, CTIP2 counteracts 
HIV-1 Vpr protein that is required for p21 expression (125). We, 
therefore, suggested that CTIP2 generates a cellular environment 
disfavoring viral reactivation and, thus, favoring HIV-1 latency.
The first CTIP2-associated complex described in our labora-
tory has been involved in the establishment of HIV-1 latency 
through the induction of heterochromatin in the vicinity of the 
FiGURe 1 | CTiP2 promotes the establishment and persistence of Hiv-1 latency through the recruitment of two macromolecular complexes on the 
Hiv-1 promoter in microglial cells. CTIP2 participates in the establishment of HIV-1 latency by recruiting a chromatin-modifying complex at the HIV-1 promoter. 
This complex consists of two histone deacetylases: HDAC1 and HDAC2 that are responsible for H3K9 deacetylation of Nuc-1, a nucleosome located immediately 
downstream of the HIV-1 transcriptional start site. The histone methyltransferase SUV39H1 takes also part of the complex and catalyzes the tri-methylation of H3K9 
on Nuc-1. Finally, HP1α, a protein associated with heterochromatin, specifically recognizes H3K9me3 and spreads along the HIV-1 promoter, thus creating a 
domain of heterochromatin refractory to transcription. In parallel, CTIP2 also recruits the histone demethylase complex LSD1/COMPASS/SET1 that, in association 
with the histone marks H3K9me3 and H3K4me3, contributes to HIV-1 gene silencing and, therefore, the establishment of HIV-1 latency. Besides, by recruiting a 
transcriptional inhibitory complex at the HIV-1 promoter, CTIP2 is also involved in the prevention of HIV-1 reactivation. This complex is an inactive form of the 
elongation factor pTEFb and consists of pTEFb, HEXIM1, HMGA1, and the snRNA 7SK. Due to their involvement in HIV-1 establishment and persistence of HIV-1 
latency, CTIP2-associated proteins from both complexes constitute new pharmacological targets to reverse HIV-1 latency. Accordingly, new latency-reversing 
agents (LRAs) are currently being developed or undergoing clinical trials with the aim of reversing HIV-1 latency and depleting HIV-1 reservoirs.
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viral promoter (Figure 1, left complex). Indeed, we showed that 
CTIP2 recruits a chromatin-modifying complex through the Sp1 
sites of the proximal promoter (42). This complex contains the 
histone deacetylases HDAC1, HDAC2, and histone methyltrans-
ferase SUV39H1 that specifically demethylates lysine 9 of histone 
H3. This histone modification allows heterochromatin protein 
1 (HP1) binding, heterochromatin formation, and hence HIV 
silencing (42, 126, 127). In a consecutive study, we have shown 
that CTIP2 interacts physically and functionally with the lysine-
specific demethylase (LSD1) to repress HIV-1 transcription and 
viral expression in a synergistic manner (128). The recruitment 
of LSD1 at the HIV-1 proximal promoter has been associated 
with both H3K4me3 and H3K9me3 epigenetic marks, which is 
linked to the recruitment of hSet1 and WDR5, two members 
of the hCOMPASS complex, on the HIV-1 promoter (128). 
Recruitment of CTIP2 on the p21 promoter also induces a het-
erochromatin environment. Moreover, CTIP2 has been shown 
to silence p21 gene transcription by creating epigenetic marks 
of repression, as described above for the HIV-1 promoter (125). 
Interestingly epigenetic regulation of HIV-1 latency, which was 
associated with the recruitment of HDACs and SUV39H1 has 
also been described in astrocytes (40). Finally, in a recent report, 
investigation of the neuropathology and the molecular alterations 
associated with CNS latent HIV-1 infections provided evidence 
that HIV-1 persistence in the brain is associated with high level 
of CTIP2, HDACs, and HP1 (39).
We also showed that CTIP2 belongs to another complex 
able to prevent HIV-1 reactivation (Figure  1, right complex) 
(129). Indeed previous work has shown that CTIP2 represses 
the late phase, Tat-dependent, of HIV-1 transcription (127). 
In the absence of the trans-activator factor Tat, an inactive 
form of the elongation factor pTEFb is found in a multiprotein 
complex, including 7SK snRNA, CTIP2, and HEXIM1 anchored 
to viral and cellular gene promoters (129). pTEFb is composed 
of a regulatory subunit CyclinT1 and a catalytic subunit CDK9, 
whose kinase activity is involved in the Ser2 phosphorylation of 
the carboxyl terminal end of the RNA polymerase II and in the 
phosphorylation of the negative transcriptional elongation fac-
tors NELF and DSIF. Following phosphorylation, the RNA pol 
II processivity significantly increases, which leads to an efficient 
transcription of genes (130). Interestingly, we have shown that 
CTIP2 drastically repressed CDK9 kinase activity in this inactive 
complex, thus, inhibited pTEFb function. Finally, we showed that 
the cellular protein high mobility group AT-hook 1 (HMGA1), 
which also belongs to the 7SK snRNA complex recruits the 
inactive CTIP2/pTEFb complex to the HIV-1 and cellular target 
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promoters (131). As a consequence, protein complexes contain-
ing CTIP2 regulate viral and endogenous gene expression, thus 
favoring HIV-1 persistence. Far more investigations are still 
needed to decipher the precise molecular mechanisms involved 
in these processes. We still do not fully understand how the 
transition from transcription initiation into elongation (which 
involves pTEFb) is controlled by cellular factors and/or the viral 
transactivator Tat. We and others hypothesized that the inactive 
form of the pTEFb complex is part of a 7SK complex that is 
anchored to the promoter by either CTIP2 (129) or Kap1 (132), 
thus available for RNApolII elongation through its activation. 
The transition from the inactive to the active form of the pTEFb 
complex through the action of Tat is not well understood but 
may involve a phosphatase (PPM1G/PP2Cγ) that takes apart 
pTEFb from the 7SK complex (133).
THeRAPeUTiC iMPLiCATiONS FOR THe 
eRADiCATiON OF Hiv-1 FROM BRAiN 
ReSeRvOiRS
Several considerations already mentioned [emergence of mul-
tidrug resistance (24, 113), non-AIDS-related events (134–136) 
etc.] urge the search of new ways to develop a sterilizing or a 
functional cure for AIDS (137). The purge of viral reservoirs 
by the “shock and kill” strategy (138) is a possible approach to 
achieve such a cure. This strategy aims at purging or at least 
reducing the size of cellular reservoirs by reactivating HIV 
transcription (shock) followed by intensive cART therapy and 
immune activation (kill) (139, 140). As several reports suggested, 
using LRA alone or in combination have proven the efficiency 
of this strategy in the reactivation of quiescent/latent HIV 
from CD4+ T-cells reservoirs (138, 141–145). Several clinical 
trials have been carried out and some others are in progress or 
forthcoming (146). This strategy of reactivation needs to work 
on all potential reservoirs, including brain reservoirs. However, 
several limitations to the eradication of the brain reservoirs may 
preclude a cure.
Limitations to the eradication of Brain 
Reservoirs
It is essential to decipher the molecular mechanisms underlying 
HIV persistence in all types of potential reservoirs, since some 
important differences in those mechanisms have been noticed 
in all latently infected cell types. For example, LSD1 has been 
associated with activation of HIV transcription in CD4+ T-cells 
(147). However, in microglial cells, LSD1 played a role in the 
establishment of latency (128). LSD1 mediates HIV-1 transcrip-
tion silencing in microglial by anchoring various factors at the 
promoter rather than inducing HIV-1 transcription by its own 
enzymatic activity in CD4+ T-cells. The dual role of LSD1 
achieved by different mechanisms in the two main HIV-1 cellular 
targets points to the complexity of the molecular mechanisms 
of HIV latency (148). Hence, additional investigations of the 
epigenetic regulation of HIV latency are needed in order to 
develop efficient drugs targeting each potential viral reservoir. 
Furthermore, as mentioned in the previous sections, there are 
several characteristics of the CNS, which limits a cure by the 
“shock and kill” strategy:
i. The CNS is a sanctuary with barriers (BBB and choroid 
plexus) that reduce the access of some of the drugs currently 
used to the brain (97).
ii. The main cellular targets are astrocytes and CNS-resident 
macrophages. However, few drugs are able to target the 
monocyte–macrophages lineage (149) and the effects of 
cART on HIV replication in astrocytes are unknown or 
neurotoxic (150).
iii. CNS has long been considered as an immunologically 
privileged site (151). Therefore, achieving immune activa-
tion through cytotoxic T lymphocytes (CTL) activation to 
eliminate the potential reservoirs may be difficult or even 
deleterious in the brain.
iv. Another major concern is related to the fact that reactivation 
of the virus with LRA will lead to the synthesis of neurotoxic 
viral proteins, such as Tat and the gp120, as there are no 
drugs currently available targeting HIV transcription. 
Moreover, reactivation of the virus is often associated with 
CNS inflammation through macrophage/microglial cell 
activation (152, 153).
How Can we Overcome These 
Limitations?
With these limitations evoked in the previous section, it may be 
difficult to achieve a purge in the CNS. The idea is to eliminate 
or reduce the pool of latent/quiescent reservoirs with the aim 
to mimic elite controllers able to control the HIV infection and 
with very low amount of reservoirs. Introducing cART very early 
following HIV infection has been proved to be efficient since it 
limits the size of the latent/quiescent reservoirs (154–156).
In our opinion, achieving a sterilizing cure or a partial 
functional cure in the brain needs efforts in four directions: (i) 
designing efficient LRA for CNS-cell types, (ii) improving cART 
by targeting HIV transcription, (iii) improving delivery of HIV 
drugs in the CNS and in the CNS-cell types, and (iv) developing 
therapeutic immunization.
Designing potent LRAs to reactivate HIV-1 transcription 
from the CNS-cell types is crucial in a “shock and kill” strategy. 
However, we and others have shown that the molecular mecha-
nisms involved in the establishment and persistence of latency 
in these cells may differ from the mechanisms involved in the 
CD4+ T-cells that are currently the main targets for LRAs (106, 
107, 137). As a consequence, the outcome in the use of LRAs 
may differ in CNS-cell types. Several HDAC inhibitors (HDACi) 
have been tested in the U1 monocyte cell line and in primary 
cells (astrocytes and macrophages) (106, 107, 157). Preliminary 
data showed that some LRAs, including panobinostat (158) and 
JQ1 (159), are relatively non-toxic and efficient to induce HIV 
reactivation at a therapeutic concentration (106, 107). On the 
contrary, other LRAs, including disulfiram and vorinostat, which 
were promising in CD4+ T-cells, were not working at therapeutic 
concentration in the CNS-cell types (106, 107). Among LRAs, 
bryostatin-1 is very promising since it can cross the BBB to 
activate brain Protein Kinase C especially in the two main targets 
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for HIV-1, i.e., microglial cells and astrocytes (142, 160). This 
PKC activator has already been used in both preclinical trials for 
Alzheimer disease and in clinical trials to treat cancers [reviewed 
in Ref. (161)]. Further investigations will be needed to character-
ize new targets, such as the hCompass complex, recruited on the 
viral promoter by LSD1 in microglial cells. Preclinical studies 
in animal models are also needed to test the efficacy of LRAs. 
Combinations of LRAs have to be tested in vitro and in vivo as 
well, since they may work in a synergistic manner as described 
(142, 162). Using combination of LRAs with lower dose may 
also prevent some drug side effects when used alone at a higher 
concentration [reviewed in Ref. (163)]. Finally, a recent pilot 
study has suggested that administration of panobinostat, a potent 
activator of HIV transcription in CNS-cell types, was not associ-
ated with side effect in the brain as assessed by CSF biomarkers, 
such as neopterin, C reactive protein, and IP-10 (164).
Improving cART by targeting HIV transcription is also cru-
cial since there are currently no drugs targeting this step (93). 
Moreover, reactivation of HIV leads to the synthesis of neurotoxic 
viral proteins, such as Tat. We and others discussed in details the 
importance of targeting this step and readers are referred to these 
recent reviews (93, 165). Particularly, inhibitors may be developed 
against the two main targets that control HIV transcription, i.e., 
the cellular factor NF-KB and the viral transactivator Tat. Since 
NF-KB also plays a central role in inflammation, new drugs 
targeting this factor will also prevent or at least reduce chronic 
inflammation in the brain (166, 167). It is also important to target 
the viral transactivator Tat since this factor is involved in the 
regulation of HIV-1 and its secreted form induces neuronal death 
by direct neurotoxicity. Several molecules, especially natural 
compounds deserve attention (168, 169). We believe that charac-
terization of new targets associated with the exploitation of new 
technologies, such as bioengineering, high-throughput screen-
ing, computer-aided drug design, and combinatorial chemistry, 
will considerably improve the discovery of new drugs. Among 
the molecules that deserve attention, we can mention the dCA, 
a chemical derivative of corticostatin, a natural steroidal alkaloid 
isolated from a sponge (170–172). A promising Tat inhibitor has 
been recently isolated from the plant Tripterygium wilfordii and 
named triptolide (173). This molecule, which is currently in phase 
III of a clinical trial, inhibits both HIV replication and transcrip-
tion by increasing the proteasomal degradation of Tat. Another 
family of protein that deserves attention is the DING proteins 
(pDINGs), a family of potential therapeutic agents against HIV-1 
(174–178). These molecules discovered in bacteria, plants, and 
animals have been reported to inhibit HIV transcription. In addi-
tion, it has been shown that a phosphorylated form of pDING 
is a neuroprotective factor and could be used to reduce neuro 
inflammation due to HIV-1 (88, 179).
Another major limitation to purge brain reservoirs is related 
to the poor access of the drugs in the CNS due to the presence 
of barriers, such as the BBB. Moreover, drugs have to target 
macrophages and astrocytes. Indeed, it has been shown that all 
drugs, except protease inhibitors, display reduced activity in 
macrophages compared to CD4+ T-cells (180). We have already 
mentioned that some LRAs have no effect in the CNS-cell types 
at a therapeutic concentration. Different mechanisms have 
been evoked to explain the lower EC50 values of these drugs 
in macrophages/microglial cells. Drug penetration may be 
reduced due to the differential expression of efflux transporter 
and multidrug resistance proteins (181, 182). Several ways are 
explored to overcome these limitations and discussed in other 
reviews (183, 184). Improvement of both bioavailability and bio-
distribution of drugs used in cART will increase the access of 
these drugs to the brain. Among the approaches used to improve 
drug delivery in the brain, there is the development of carriers, 
such as liposomes, dendrimers, and micelles. A particularly 
promising approach is based on polymeric nanomedicines that 
raise hope for eradication of HIV from all potential reservoirs 
[reviewed in Ref. (185–187)]. Increase in treatment efficacy and 
tolerance may be expected, hence favoring patient adherence. 
These later strategies may also increase the distribution of drugs 
in CNS-cell types, such as astrocytes and macrophages/ microglial 
cells. Indeed, macrophages/microglial cells constitute an impor-
tant but neglected barrier for HIV eradication, which will need 
efforts to circumvent (149, 188). Several conventional and new 
therapeutics against HIV-1 in macrophages, including PI3K/
Akt blocking agents, carbohydrate-binding agents, and small 
interfering RNAs, have been discussed elsewhere and deserve 
real attention (184, 189).
Immune-based therapeutics should also be considered since 
the size of the reservoir following treatment with LRAs is not 
reduced and need immune activation to clear them (190). In 
particular, CTL activation has been shown to clear HIV-1 from 
infected CD4+ T-cells (140). Previous studies done in animal 
models argued in favor of the importance of CTL in the clearance 
of HIV-1 infected macrophages in the brain (191, 192). A CD8+ 
T-cell response appears essential in the control of other brain 
infections, such as toxoplasmosis (193). Dealing with immune 
activation is not easy and constitutes a challenge for strategies 
aiming to eradicate HIV-1 reservoirs. These approaches need 
further investigations and development of adequate animal 
models to ensure the feasibility of such treatments (194, 195). 
Another unexplored non-conventional way to clear reactivated 
latently infected cells is based on the use of neutralizing antibod-
ies against HIV-1 with promising results obtained in humanized 
mice (143, 196).
CONCLUSiON
Reducing the size of reservoirs is fundamental for HIV+ 
patients to control their viral replication without any treat-
ment, a situation typical for elite controllers. The purge of HIV 
reservoirs constitutes, therefore, one of the top research priority 
of the International AIDS Society (IAS) through the action 
“Toward an HIV Cure.” We may expect to get a sterilizing 
cure by eradicating the virus from all the reservoirs but a more 
realistic view would be a functional cure through the reduc-
tion of the pool of cellular reservoirs. A major problem is to 
reduce/eradicate reservoirs located in the CNS. There are now 
numerous direct and indirect arguments for the existence of a 
pool of quiescent/latent reservoirs in the brain even if it has not 
been demonstrated in human yet. The strategy called “shock 
and kill” enables reactivation of quiescent/latent reservoirs 
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followed by an intensive cART to clear the reservoirs. Several 
pilot clinical trials have been done and some are ongoing and 
upcoming. The results of trials are encouraging but also point 
to the need of additional interventions, such as immune activa-
tion, in order to clear the reservoirs. This immune activation 
approach is needed to eliminate or reduce brain reservoirs 
but might be difficult since the CNS has several unique char-
acteristics. Indeed, the CNS is a pharmacological sanctuary 
and a compartment isolated from the other parts of the body. 
In addition, latently infected cells in the brain, i.e., astrocytes 
and macrophages/microglial cells are rather different from the 
main memory T-cells reservoir. Altogether, intense efforts are 
needed in several directions, including the design of efficient 
LRAs for CNS-cell types, improving cART by targeting HIV 
transcription, improving delivery of HIV drugs in the CNS and 
in the CNS-cell types and developing therapeutic immunization 
therapies in order to overcome the above discussed limitations. 
We believe that we are at a crossroads to achieve a cure for 
HIV. Indeed, there are several adequate animal models (non-
human primate, humanized mice, etc.) to test the efficiency 
of strategies aiming to purge reservoirs. Identification of new 
targets and the availability of new technologies will also allow 
the design of new original drugs. In particular, new natural 
compounds and their derivatives could help in the design of 
new class of molecules targeting HIV-1 transcription a step not 
yet targeted by cART. This is especially crucial in a strategy 
aiming to reactivate latent CNS-cell types. Finally, hope rises 
also with the advent of nanotechnologies. Although still in the 
early stage, nanotechnologies could be used in drug transport to 
enable drugs to reach both the brain (by crossing barriers such as 
the BBB) and the CNS-cell types (by crossing cell membranes). 
Dosage is expected lower and in consequence less toxicity and 
a better adherence to treatment is awaited.
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